Terumo Aortic announced today the completion of enrolment of the Relay®Pro Traumatic Injury (Relay®Pro–T) Investigational Device Exemption (IDE) study in the United States. Relay®Pro is a low profile, next generation thoracic stent graft device designed to expand the treatment of thoracic endovascular aortic repair (TEVAR) to patients with smaller access vessels.
Following recent approval by the US Food and Drug Administration (FDA) of the TREO® Abdominal Aortic Stent-Graft System for the treatment of patients with abdominal aortic aneurysms (AAA), Terumo Aortic announced today the publication of the primary endpoint results from the investigational device exemption (IDE) pivotal study in the Journal of Vascular Surgery.
Please reach out to our media relations contact for press
enquiries about our innovative solutions.
Head, Global Marketing Communications
+44 (0) 141 812 5555
This website uses anonymous cookies to provide you with a better user experience.
A cookie is a small text-file allows a website to remember a user and their preferences. They are very common, and most websites use them. Otherwise you'd need to set your preferences again on each page you visited.
Strictly Necessary Cookies
Functional Cookies are enabled at all times, to enable this website to function correctly and to save your preferences.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
This website uses Google Analytics to collect anonymous information such as the number of visitors and the most popular pages.
Keeping this cookie enabled helps us to identity trends, spot problems and improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!